ArticleThe British journal of radiology2026
Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial.
Article in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTotal neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) often uses intensive oxaliplatin-based chemotherapy alongside standard radiotherapy to prevent metastatic progression. The optimal intensity of the chemotherapy component, given a contribution of radiotherapy to clonogenic cell elimination in the primary tumor, remains uncertain. We aimed to assess long-term outcomes of a TNT regimen with low-intensity induction chemotherapy before chemoradiotherapy, as evaluated in the LARC-RRP trial.
methodsBetween 2005 and 2010, 87 LARC patients (36% with T4 organ-infiltrating tumor) were enrolled in the single-arm trial. Induction chemotherapy was given over 4 weeks prior to chemoradiotherapy and surgery. We report 10-year overall survival by tumor regression grade (TRG) and performed descriptive comparisons with contemporary trials whose experimental TNT arms used more intensive chemotherapy.
resultsAt 10 years, overall survival was 83% (95% confidence interval, 71-90) for patients with complete or near-complete tumor cell elimination in the surgical specimen (TRG 1-2; 70% of the cohort) versus 52% (95% confidence interval, 31-69) for others (log-rank P = .0005). LARC-RRP survival outcomes were comparable with those reported in more contemporary TNT trials.
conclusionsThe LARC-RRP results raise the possibility that shorter-duration chemotherapy combined with standard radiotherapy may suffice to protect against systemic recurrence of high-risk LARC. ADVANCES IN KNOWLEDGE: These long-term data support investigation of less intensive chemotherapy within TNT regimens and may guide the design of risk-stratified TNT trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.